The Italian biotechnology company MolMed has announced positive results for their Phase II trial of NGR-hTNF for the treatment of malignant pleural mesothelioma.The trial, which consisted of 57 malignant pleural mesothelioma patients that were previously treated with chemotherapy, found NGR-hTNF useful as both a theraputic option and as part of a combination therapy with most chemotherapy methods.
During the trial, one group of patients received the drug every three weeks and the other received it each week. Both groups received low doses of the drug intravenously. The results of the trial showed a median overall survival rate of one year. The disease control rate during the trial was 46 percent, which was maintained for a median total duration of 4.7 months.
MolMed plans to start another Phase II trial of NGR-hTNF in combination with cisplatin for lung cancer. Cisplatin, a chemotherapy drug that is often combined with newer medications ton increase the effectiveness of treatment, is one of the most effective treatment options available for pleural mesothelioma when combined with another chemotherapy drug called Alimta.
Mesothelioma is a form of cancer that is linked to asbestos exposure. Workplace exposure to asbestos in places like aluminum smelters, oil refineries, shipyards and the construction industry puts workers at risk of developing asbestos-related diseases like asbestosis, lung cancer, gastrointestinal cancer and mesothelioma.
0 comments:
Post a Comment